GlaxoSmithKline will receive $94m from the US Department of Health and Human Services to support research and clinical testing for a promising new antibiotic that could be used to treat pneumonia and bio-terror threats.

The antibiotic, GSK ‘052, was originally discovered by Anacor Pharmaceuticals. It will be moved to mid-stage trial for ventilator-associated pneumonia and a late-stage study for complicated intra-abdominal infections.

Anacor licensed the compound to GlaxoSmithKline last year and received an option exercise fee of $15 million.

The company is also eligible for future development milestone payments of up to $75.5 million and commercial milestone payments of up to $175m as well as royalty payments.

GlaxoSmithKline will be responsible for development and commercialisation of GSK ‘052.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData